Skip to main content

Therapeutic vaccines for aggressive B-cell lymphoma.

Publication ,  Journal Article
Xu-Monette, ZY; Young, KH
Published in: Leukemia & lymphoma
December 2020

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma and highly heterogeneous disease. With the standard immunochemotherapy, anti-CD20 antibody rituximab (R-) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, 30-40% of DLBCLs are refractory to initial immunochemotherapy or experience relapse post-therapy with poor clinical outcomes despite salvage therapies. Mechanisms underlying chemoresistance and relapse are heterogeneous across DLBCL and within individual patients, representing hurdles for targeted therapies targeting a specific oncogenic signaling pathway. In recent years, paradigm-shifting immunotherapies have shown impressive efficacy in various cancer types regardless of underlying oncogenic mechanisms. Vaccines are being developed for DLBCL to build protective immunity against relapse after first complete remission and to promote antitumor immune responses synergizing with immune checkpoint inhibitors to treat refractory/relapsed patients. This article provides a brief review of current progress in vaccine development in DLBCL and discussion on immunologic mechanisms underlying the therapeutic effectiveness and resistance.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leukemia & lymphoma

DOI

EISSN

1029-2403

ISSN

1042-8194

Publication Date

December 2020

Volume

61

Issue

13

Start / End Page

3038 / 3051

Related Subject Headings

  • Vincristine
  • Vaccines
  • Rituximab
  • Prednisone
  • Neoplasm Recurrence, Local
  • Lymphoma, Large B-Cell, Diffuse
  • Immunology
  • Humans
  • Doxorubicin
  • Cyclophosphamide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xu-Monette, Z. Y., & Young, K. H. (2020). Therapeutic vaccines for aggressive B-cell lymphoma. Leukemia & Lymphoma, 61(13), 3038–3051. https://doi.org/10.1080/10428194.2020.1805113
Xu-Monette, Zijun Y., and Ken H. Young. “Therapeutic vaccines for aggressive B-cell lymphoma.Leukemia & Lymphoma 61, no. 13 (December 2020): 3038–51. https://doi.org/10.1080/10428194.2020.1805113.
Xu-Monette ZY, Young KH. Therapeutic vaccines for aggressive B-cell lymphoma. Leukemia & lymphoma. 2020 Dec;61(13):3038–51.
Xu-Monette, Zijun Y., and Ken H. Young. “Therapeutic vaccines for aggressive B-cell lymphoma.Leukemia & Lymphoma, vol. 61, no. 13, Dec. 2020, pp. 3038–51. Epmc, doi:10.1080/10428194.2020.1805113.
Xu-Monette ZY, Young KH. Therapeutic vaccines for aggressive B-cell lymphoma. Leukemia & lymphoma. 2020 Dec;61(13):3038–3051.

Published In

Leukemia & lymphoma

DOI

EISSN

1029-2403

ISSN

1042-8194

Publication Date

December 2020

Volume

61

Issue

13

Start / End Page

3038 / 3051

Related Subject Headings

  • Vincristine
  • Vaccines
  • Rituximab
  • Prednisone
  • Neoplasm Recurrence, Local
  • Lymphoma, Large B-Cell, Diffuse
  • Immunology
  • Humans
  • Doxorubicin
  • Cyclophosphamide